Loss of CCR2 expressing non-classical monocytes are associated with cognitive impairment in antiretroviral therapy-naïve HIV-infected Thais

Journal of Neuroimmunology

Volumn 288, Issue , 2015, Pages 25-33

  Ndhlovu, Lishomwa C ^a   D'Antoni, Michelle L ^a   Ananworanich, Jintanat ^b,d,g   Byron, Mary Margaret ^a   Chalermchai, Thep ^a   Sithinamsuwan, Pasiri ^c   Tipsuk, Somporn ^a   Ho, Erika ^a   Slike, Bonnie M ^d,g   Schuetz, Alexandra ^d,e   Zhang, Guangxiang ^a   Agsalda Garcia, Melissa ^a   Shiramizu, Bruce ^a   Shikuma, Cecilia M ^a   Valcour, Victor ^f  

^a UNIVERSITY OF HAWAII   (United States)

^b SEARCH   (Thailand)

^c THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

C C chemokine receptor (CCR) CCR2; CD163; HIV associated neurocognitive disorders (HAND); Monocytes; Neopterin

Indexed keywords

BIOLOGICAL MARKER; CD163 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NEOPTERIN; TUMOR NECROSIS FACTOR ALPHA; CCR2 PROTEIN, HUMAN; VIRUS DNA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MONOCYTE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; TASK PERFORMANCE; THAI (PEOPLE); ASIAN CONTINENTAL ANCESTRY GROUP; COGNITIVE DEFECT; FLOW CYTOMETRY; IMMUNOLOGY; THAILAND; VIROLOGY;

ADULT; AIDS DEMENTIA COMPLEX; ASIAN CONTINENTAL ANCESTRY GROUP; COGNITION DISORDERS; DNA, VIRAL; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MONOCYTES; RECEPTORS, CCR2; THAILAND;

EID: 84945543480     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2015.08.020     Document Type: Article

References (43)

1. Abdulle S., Hagberg L., Svennerholm B., Fuchs D., Gisslen M. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS 2002, 16:2145-2149.
2. Abeles R.D., McPhail M.J., Sowter D., Antoniades C.G., Vergis N., Vijay G.K., et al. CD14, CD16 and HLA-DR reliably identifies human monocytes and their subsets in the context of pathologically reduced HLA-DR expression by CD14(hi)/CD16(neg) monocytes: Expansion of CD14(hi)/CD16(pos) and contraction of CD14(lo)/CD16(pos) monocytes in acute liver failure. Cytometry A 2012, 81:823-834.
3. Ancuta P., Kamat A., Kunstman K.J., Kim E.Y., Autissier P., Wurcel A., et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 2008, 3:e2516.
4. Antinori A., Arendt G., Becker J.T., Brew B.J., Byrd D.A., Cherner M., et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69:1789-1799.
5. Bernasconi S., Cinque P., Peri G., Sozzani S., Crociati A., Torri W., et al. Selective elevation of monocyte chemotactic protein-1 in the cerebrospinal fluid of AIDS patients with cytomegalovirus encephalitis. J. Infect. Dis. 1996, 174:1098-1101.
6. Brew B.J., Bhalla R.B., Paul M., Gallardo H., McArthur J.C., Schwartz M.K., et al. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann. Neurol. 1990, 28:556-560.
7. Campbell J.H., Ratai E.M., Autissier P., Nolan D.J., Tse S., Miller A.D., et al. Anti-alpha4 antibody treatment blocks virus traffic to the brain and gut early, and stabilizes CNS injury late in infection. PLoS Pathog. 2014, 10:e1004533.
8. Cassol E., Misra V., Morgello S., Gabuzda D. Applications and limitations of inflammatory biomarkers for studies on neurocognitive impairment in HIV infection. J. Neuroimmune Pharmacol. 2013, 8:1087-1097.
9. Conant K., Garzino-Demo A., Nath A., McArthur J.C., Halliday W., Power C., et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:3117-3121.
10. Dutertre C.A., Amraoui S., DeRosa A., Jourdain J.P., Vimeux L., Goguet M., et al. Pivotal role of M-DC8(+) monocytes from viremic HIV-infected patients in TNFalpha overproduction in response to microbial products. Blood 2012, 120:2259-2268.
11. Ellis R.J., Deutsch R., Heaton R.K., Marcotte T.D., McCutchan J.A., Nelson J.A., et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch. Neurol. 1997, 54:416-424.
12. Faissner S., Ambrosius B., Schanzmann K., Grewe B., Potthoff A., Munch J., et al. Cytoplasmic HIV-RNA in monocytes determines microglial activation and neuronal cell death in HIV-associated neurodegeneration. Exp. Neurol. 2014, 261:685-697.
13. Fischer-Smith T., Tedaldi E.M., Rappaport J. CD163/CD16 coexpression by circulating monocytes/macrophages in HIV: potential biomarkers for HIV infection and AIDS progression. AIDS Res. Hum. Retrovir. 2008, 24:417-421.
14. Fuchs D., Chiodi F., Albert J., Asjo B., Hagberg L., Hausen A., et al. Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. AIDS 1989, 3:285-288.
15. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5:953-964.
16. Hagberg L., Cinque P., Gisslen M., Brew B.J., Spudich S., Bestetti A., et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res. Ther. 2010, 7:15.
17. Heaton R.K., Marcotte T.D., Mindt M.R., Sadek J., Moore D.J., Bentley H., et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J. Int. Neuropsychol. Soc. 2004, 10:317-331.
18. Ickovics J.R., Hamburger M.E., Vlahov D., Schoenbaum E.E., Schuman P., Boland R.J., et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001, 285:1466-1474.
19. Jalbert E., Crawford T.Q., D'Antoni M.L., Keating S.M., Norris P.J., Nakamoto B.K., et al. IL-1Beta enriched monocytes mount massive IL-6 responses to common inflammatory triggers among chronically HIV-1 infected adults on stable anti-retroviral therapy at risk for cardiovascular disease. PLoS One 2013, 8:e75500.
20. Jalbert E., Shikuma C.M., Ndhlovu L.C., Barbour J.D. Sequential staining improves detection of CCR2 and CX3CR1 on monocytes when simultaneously evaluating CCR5 by multicolor flow cytometry. Cytometry A 2013, 83:280-286.
21. Kelder W., McArthur J.C., Nance-Sproson T., McClernon D., Griffin D.E. Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann. Neurol. 1998, 44:831-835.
22. Kusao I., Shiramizu B., Liang C.Y., Grove J., Agsalda M., Troelstrup D., et al. Cognitive performance related to HIV-1-infected monocytes. J. Neuropsychiatry Clin. Neurosci. 2012, 24:71-80.
23. Ndhlovu L.C., Umaki T., Chew G.M., Chow D.C., Agsalda M., Kallianpur K.J., et al. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). J. Neurovirol. 2014, 20:571-582.
24. Perrella O., Carrieri P.B., Guarnaccia D., Soscia M. Cerebrospinal fluid cytokines in AIDS dementia complex. J. Neurol. 1992, 239:387-388.
25. Probasco J.C., Deeks S.G., Lee E., Hoh R., Hunt P.W., Liegler T., et al. Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation. AIDS 2010, 24:1001-1005.
26. Pulliam L., Gascon R., Stubblebine M., McGuire D., McGrath M.S. Unique monocyte subset in patients with AIDS dementia. Lancet 1997, 349:692-695.
27. Rusconi S., Vitiello P., Adorni F., Colella E., Foca E., Capetti A., et al. Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial. PLoS One 2013, 8:e80157.
28. Schifitto G., Zhang J., Evans S.R., Sacktor N., Simpson D., Millar L.L., et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 2007, 69:1314-1321.
29. Sevigny J.J., Albert S.M., McDermott M.P., McArthur J.C., Sacktor N., Conant K., et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004, 63:2084-2090.
30. Shapshak P., Kangueane P., Fujimura R.K., Commins D., Chiappelli F., Singer E., et al. Editorial neuroAIDS review. AIDS 2011, 25:123-141.
31. Shiramizu B., Ananworanich J., Chalermchai T., Siangphoe U., Troelstrup D., Shikuma C., et al. Failure to clear intra-monocyte HIV infection linked to persistent neuropsychological testing impairment after first-line combined antiretroviral therapy. J. Neurovirol. 2012, 18:69-73.
32. Sippy B.D., Hofman F.M., Wallach D., Hinton D.R. Increased expression of tumor necrosis factor-alpha receptors in the brains of patients with AIDS. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1995, 10:511-521.
33. Sonnerborg A.B., von Stedingk L.V., Hansson L.O., Strannegard O.O. Elevated neopterin and beta 2-microglobulin levels in blood and cerebrospinal fluid occur early in HIV-1 infection. AIDS 1989, 3:277-283.
34. Tallone T., Turconi G., Soldati G., Pedrazzini G., Moccetti T., Vassalli G. Heterogeneity of human monocytes: an optimized four-color flow cytometry protocol for analysis of monocyte subsets. J. Cardiovasc. Transl. Res. 2011, 4:211-219.
35. Tozzi V., Balestra P., Salvatori M.F., Vlassi C., Liuzzi G., Giancola M.L., et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J. Acquir. Immune Defic. Syndr. 2009, 52:56-63.
36. Tyor W.R., Glass J.D., Griffin J.W., Becker P.S., McArthur J.C., Bezman L., et al. Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann. Neurol. 1992, 31:349-360.
37. Uleri E., Mei A., Mameli G., Poddighe L., Serra C., Dolei A. HIV Tat acts on endogenous retroviruses of the W family and this occurs via Toll-like receptor4: inference for neuroAIDS. AIDS 2014, 28:2659-2670.
38. Valcour V.G., Ananworanich J., Agsalda M., Sailasuta N., Chalermchai T., Schuetz A., et al. HIV DNA reservoir increases risk for cognitive disorders in cART-naive patients. PLoS One 2013, 8:e70164.
39. Williams D.W., Calderon T.M., Lopez L., Carvallo-Torres L., Gaskill P.J., Eugenin E.A., et al. Mechanisms of HIV entry into the CNS: increased sensitivity of HIV infected CD14+CD16+ monocytes to CCL2 and key roles of CCR2, JAM-A, and ALCAM in diapedesis. PLoS One 2013, 8:e69270.
40. Williams D.W., Byrd D., Rubin L.H., Anastos K., Morgello S., Berman J.W. CCR2 on CD14(+)CD16(+) monocytes is a biomarker of HIV-associated neurocognitive disorders. Neurol. Neuroimmunol. Neuroinflammation 2014, 1:e36.
41. Wong K.L., Yeap W.H., Tai J.J., Ong S.M., Dang T.M., Wong S.C. The three human monocyte subsets: implications for health and disease. Immunol. Res. 2012, 53:41-57.
42. Zawada A.M., Rogacev K.S., Rotter B., Winter P., Marell R.R., Fliser D., et al. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 2011, 118:e50-e61.
43. Ziegler-Heitbrock L., Ancuta P., Crowe S., Dalod M., Grau V., Hart D.N., et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010, 116:e74-e80.